Last reviewed · How we verify
Atorvastatin, Ezetimibe
Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action.
Atorvastatin inhibits HMG-CoA reductase to lower LDL cholesterol, while ezetimibe blocks intestinal cholesterol absorption, providing dual lipid-lowering action. Used for Hypercholesterolemia and dyslipidemia, Cardiovascular disease risk reduction.
At a glance
| Generic name | Atorvastatin, Ezetimibe |
|---|---|
| Sponsor | Abant Izzet Baysal University |
| Drug class | Statin and cholesterol absorption inhibitor combination |
| Target | HMG-CoA reductase; NPC1L1 transporter |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Mechanism of action
Atorvastatin is a statin that reduces cholesterol synthesis in the liver by inhibiting the rate-limiting enzyme HMG-CoA reductase, thereby decreasing LDL cholesterol and triglycerides. Ezetimibe selectively inhibits cholesterol absorption in the small intestine by blocking the Niemann-Pick C1-like 1 (NPC1L1) transporter. Together, they provide complementary mechanisms to achieve greater LDL reduction than either agent alone.
Approved indications
- Hypercholesterolemia and dyslipidemia
- Cardiovascular disease risk reduction
Common side effects
- Myalgia (muscle pain)
- Elevated liver enzymes
- Headache
- Gastrointestinal upset
Key clinical trials
- A Prospective, Open, Observational Study to Confirm the Lipid-lowering Effect, Changes in Glucose Metabolism, and Safety After 6 Months of Administration of Atostazet to Hypercholesterolemic Patients 65 Years of Age or Older
- A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events (PHASE3)
- Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma (EARLY_PHASE1)
- Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study) (NA)
- A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia
- Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid / Ezetimibe, and Atorvastatin (PHASE1)
- A Study Evaluating Bioequivalence of a Fixed Dose Combination Versus Individual Tablets of Bempedoic Acid, Ezetimibe, and Atorvastatin (PHASE1)
- Intensive Lipid-lowering for Plaque and Major Adverse Cardiovascular Events in Low to Intermediate 10-year ASCVD Risk Population (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Atorvastatin, Ezetimibe CI brief — competitive landscape report
- Atorvastatin, Ezetimibe updates RSS · CI watch RSS
- Abant Izzet Baysal University portfolio CI